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Europe,thispracticeis lessconsistentlyusedintheUnitedStates.
However, these studies do not constitute level I evidence, and
thus, there is no worldwide consensus regarding endophthal-
mitis prophylaxis with cataract surgery.6
Limitations. This study is limitedby its retrospectivenatureand
the possibility of selection bias. The mechanism of this in-
creasingnonsusceptibility to fluoroquinolones is not fullyun-
derstood,but itmaybeassociatedwithwidespreaduseof fluo-
roquinolones, use of antibiotics outside of the health care
sector, and emergence of intrinsic genetic factors promoting
resistance. Although this study involves only in vitro testing,
the clinical implications of this laboratory data requires fur-
ther investigations.
Jack D. Stringham, MD
Nidhi Relhan, MD
Darlene Miller, DHSc, CIC
Harry W. Flynn Jr, MD
Author Affiliations: Bascom Palmer Eye Institute, Department of
Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida.
Corresponding Author:HarryW. Flynn Jr, MD, Bascom Palmer Eye Institute,
Department of Ophthalmology, University of Miami Miller School of Medicine,
900 NW 17th St, Miami, FL 33136 (hflynn@med.miami.edu).
Accepted for Publication: April 9, 2017.
Published Online: June 15, 2017. doi:10.1001/jamaophthalmol.2017.1826
Author Contributions:Drs Stringham and Flynn had full access to all of the data
in the study and take responsibility for the integrity of the data and the accuracy
of the data analysis.
Concept and design: Stringham, Flynn.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Stringham.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support:Miller, Flynn.
Supervision:Miller, Flynn.
Conflict of Interest Disclosures: All authors have completed and submitted the
ICMJE Form for Disclosure of Potential Conflicts of Interest and none were
reported.
Funding/Support: This research work was supported in part by National
Institutes of Health Center Core grant P30EY014801 and a Research to Prevent
Blindness Unrestricted Grant.
Role of the Funder/Sponsor: The funding organizations had no role in the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; preparation, review, or approval of themanuscript;
and decision to submit themanuscript for publication.
1. Schimel AM, Miller D, Flynn HW. Evolving fluoroquinolone resistance among
coagulase-negative Staphylococcus isolates causing endophthalmitis. Arch
Ophthalmol. 2012;130(12):1617-1618.
2. Dave SB, Toma HS, Kim SJ. Ophthalmic antibiotic use andmultidrug-resistant
staphylococcus epidermidis: a controlled, longitudinal study.Ophthalmology.
2011;118(10):2035-2040.
3. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year
results of a longitudinal controlled study of patients undergoing intravitreal
injections. Arch Ophthalmol. 2011;129(9):1180-1188.
4. Chiquet C, Maurin M, Altayrac J, et al. Correlation between clinical data and
antibiotic resistance in coagulase-negative Staphylococcus species isolated
from 68 patients with acute post-cataract endophthalmitis. Clin Microbiol Infect.
2015;21(6):592.e1-592.e8.
5. Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with
intracameral moxifloxacin prophylaxis: analysis of 600000 surgeries.
Ophthalmology. 2017;S0161-6420(16)30790-4.
6. Grzybowski A, Schwartz SG, Matsuura K, et al. Endophthalmitis prophylaxis
in cataract surgery: overview of current practice patterns around the world. Curr
Pharm Des. 2017;23(4):565-573.
OBSERVATION
IntravitrealMelphalan for Treatment of Primary
Vitreoretinal Lymphoma: ANew Indication
for anOld Drug
Primary vitreoretinal lymphoma (PVRL) is a malignant large
B-cell lymphoma affecting the eye and brain, with 5-year
cumulative survival rate of 35% in those with brain involve-
ment (68% in those without).1 Ocular involvement mani-
fests with aggregated tumor cells in the vitreous, retina,
optic disc, and subretinal pigment epithelial space. Manage-
ment involves treatment of both eyes and brain, and treat-
ment options for the eye(s) include systemic chemotherapy,
external radiotherapy, or intravitreal injection of chemo-
therapy.
Themostcommonlyused intravitrealmedication forPVRL
is methotrexate.2,3 Others have investigated intravitreal
rituximab.4 Herein, we report our experience with melpha-
lan, a medication commonly used for treatment of vitreous
seeding from retinoblastoma,5,6 in 3 eyes of 2 patients with
PVRL. Bothmethotrexate andmelphalan have been used for
retinoblastoma, andmethotrexate requires approximately 25
injections/y, whereas melphalan needs fewer at 4 to 6 injec-
tions/y, the latter achieving retinoblastoma seed control in up
to 100% of cases.3,6
Melphalan is a well-established alkylating agent, devel-
oped in 1953 and used to treat several hematologic malig-
nancies, including lymphoma, leukemia, and multiple
myeloma, as well as solid tumors including breast, ovarian,
and neural cancers.5 When used in the vitreous for retino-
blastoma, filtered preparation of 20 μg/0.1 mL is sufficient
for tumor control.6 Owing to its effect on lymphoma and our
experience with this medication, we challenged PVRL with
melphalan.
Methods | This retrospective investigation was approved by
the institutional review board of Wills Eye Hospital. Three
eyes of 2 patients with biopsy-confirmed PVRL were offered
standard treatment or intravitreal melphalan (low dose [10
μg/0.1 mL]). Following written consent, the medication was
injected into the vitreous using sterile technique. Clinical
features and outcomes were recorded.
Results | Case 1. A92-year-oldwomanwith vitrectomy-proven
bilateral PVRL (large B-cell lymphoma cytology) demon-
strated severe vitreous tumor infiltration in the right eye and
mild infiltration in the left eye, with subretinal pigment epi-
thelial tumor in the left eye (Figure 1). Visual acuity was
20/30 OD and 20/40 OS. She was treated with low-dose intra-
vitreal melphalan (10 μg/0.1 mL) to both eyes. Following ini-
tial injection, complete clearance of vitreous tumor in both
eyes was noted within 3 weeks. During the 19-month follow-
up, the right eye required 6 bimonthly injections for minor
seed recurrence, and the left eye remained stable without
recurrence. There were no toxicities in either eye, but the left
eye showed stable focal subfoveal fluid, with mild macular
edema at presentation and throughout her course. Final
visual acuity was 20/50 OU.
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Case2. A65-year-oldmanwithchronicuveitis inbotheyesand
vitrectomy-proven PVRL (large B-cell lymphoma cytology)
demonstratedmoderatevitreous tumor inbotheyes (Figure2).
At treatment, visual acuitywas20/150ODand20/400OS.The
right eye was treatedwith intravitreal melphalan and the left
eye with intravitreal methotrexate. The right eye demon-
strated rapid improvement of visual acuitywithin 2 days (per
patient observation) andmeasured 20/50 at 1 month, requir-
ing no further melphalan injections over 16 months follow-
up, whereas the left eye showed slower response and a total
of 19 injectionsofmethotrexateover 11months follow-up.Both
eyes showed intermittent cystoid macular edema from uve-
itis, and final visual acuity was 20/50 OD and 20/70 OS.
A summary of the 3 eyes with PVRL revealed rapid re-
sponse to low-dose intravitrealmelphalan,with complete vit-
reous tumor clearance in 2 cases following a single injection
and tumor control following multiple injections in one case.
There was no retinal toxicity.
Figure 1. Case 1: A 92-Year-OldWoman
Baseline fundus photograph, right eyeA
Baseline optical coherence tomography, right eyeC
1-mo Follow-up, right eyeE
13-mo Follow-up, right eyeG
Baseline fundus photograph, left eyeB
Baseline optical coherence tomography, left eyeD
1-mo Follow-up, left eyeF
13-mo Follow-up, left eyeH
A 92-year-old womanwith visual
acuity of 20/30 OD and 20/40 OS
and biopsy-proven posterior
vitreoretinal lymphoma showed
dense vitreous infiltrate in the right
eye (A) andmild vitreous infiltrate in
the left eye (B) with peripheral
multifocal retinal pigment epithelial
infiltrates. Optical coherence
tomography showed hazy view of the
fovea in the right eye from vitreous
opacification and intraretinal edema
with shallow subretinal fluid in the
left eye (C and D). Following 1
injection of intravitreal melphalan to
each eye, complete clearance of
vitreous cells was documented in
both eyes (E and F) at 1 month.
Optical coherence tomography
showed a normal right fovea (G) and
unchanged edema and subretinal
fluid in the left eye (H). Final visual
acuity was 20/50 OU at 16months’
follow-up.
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Discussion |These 3 eyeswith PVRLdemonstrate that intravit-
real melphalan, currently used for vitreous seeds from
retinoblastoma,6 can result invitreous lymphomacontrolwith
few injections. Given the limited number of cases and rela-
tively short follow-up, further investigation seems war-
ranted to determine efficacy, safety, and appropriate treat-
ment regimen.
Carol L. Shields, MD
Kareem Sioufi, MD
ArmanMashayekhi, MD
Jerry A. Shields, MD
Author Affiliations:Ocular Oncology Service, Wills Eye Hospital, Thomas
Jefferson University, Philadelphia, Pennsylvania.
Figure 2. Case 2: A 65-Year-OldMan
Baseline fundus photograph, right eyeA
Baseline optical coherence tomography, right eyeC
Fundus photograph following melphalan injection,
right eye
E
13-mo Follow-up, right eyeG
Baseline fundus photograph, left eyeB
Baseline optical coherence tomography, left eyeD
Fundus photograph following 13 methotrexate injections,
left eye
F
13-mo Follow-up, left eyeH
A 65-year-old man with visual acuity
of 20/150 OD and 20/400OSwith
chronic posterior uveitis and
biopsy-proven posterior vitreoretinal
lymphoma showedmoderate
vitreous infiltrate in both eyes at the
time of treatment (A and B). Optical
coherence tomography showed trace
macular edema in the right eye (C)
and shallow subretinal debris in the
left eye (D). Following a single
melphalan injection in the right eye
(E), complete clearance of vitreous
cells was documented and persisted
until last examination. Following 13
injections of methotrexate in the left
eye (F), vitreous clearance was noted.
At last examination, optical
coherence tomography documented
trace foveal edema in the right eye
(G) andmoderate macular edema in
the left eye (H). At 13 months, final
visual acuity was 20/50 OD and
20/70 OS.
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COMMENT&RESPONSE
Patient CoauthoredHistory Could Improve
Health Record Accuracy
To the EditorThe article byValikodath et al1 showcases a prob-
lemwithmodern health records: documentation does not al-
waysmatch thepatient’s concerns. The authors conclude that
electronicmedical recorddatamaynot provide a comprehen-
sive resource for clinical practice or “big data” research.
I agree that a solution may come from patient-generated
information. In a previous report,2 patients were invited to
complete a replica of a history as defined by the Centers for
Medicare andMedicaid Services. Patients completed a 3-page
prehistory form with approximately 30 questions in a struc-
tured format that includedchief complaint(s), a historyofpre-
sent illness, the status of chronic condition(s), a reviewof sys-
tems, and a past family social history.3
A total of 263 patients whowere aged 14 to 94 years com-
pleted the form in preparation for a family physician visit. On
arriving to theoffice, theprehistory formwas scanned into the
electronic health record as a document and the content was
transcribed by a staff member into the history component of
the encounter note. The prehistory was recognized as a writ-
ten request to amend the health record per the Health Insur-
ancePortability andAccountabilityAct PrivacyRule (45C.F.R.
§ 164.526).
I was the physician who conducted the medical encoun-
ters for patients with a prehistory and I can attest to the im-
provement inmedical record accuracy. I was able to enter the
examination room, greet the patient, and then read the pa-
tient’s narrative, all ofwhichwas documented in the record. I
finished the history with specific questions and then per-
formed a pertinent examination. Any medical decision mak-
ing occurring readily transformed to shared decision making
because the patientswere engaged and Iwas relieved of cleri-
cal burdens.
After seeing the physician, each patient was given a pa-
per copy of the encounter note at the checkout window. Pa-
tientswere instructed to gohome, read their record, and score
it with an anonymous survey. Patients who completed a pre-
history form in preparation for amedical encounter reported
feeling better heard and understood.
Medical record inaccuracy could adversely affect patient
safety anddata analytics. These comments suggest that a pre-
history form potentially may be ameans of improving health
record accuracy.
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Incorporating Clinical, Histological,
and Genetic Parameters for Choroidal
MelanomaPrognostication
Walter et al1 recently reported that tumor diameter measure-
ment enhances thepredictionofmetastatic disease fromclass
2uvealmelanoma(UM),asclassifiedwithgeneexpressionpro-
filing. They advocate combining these 2 predictors when es-
timating prognoses.
Weagreewith this recommendation. Since 2007,wehave
publishedseveral articles emphasizing the importanceof com-
biningclinical,histologic, andgenetic survivalpredictorswhen
estimating a prognosis for UMposttreatment.2We developed
an online prognostic tool predicting survival usingmultivari-
able analyses, also accounting for age and sex.2 Walter et al1
have not cited these articles, so their Discussion does not in-
terpret their results by taking into consideration all other rel-
evant evidence in the literature.
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